WASHINGTON — Following the launch of TrumpRx, a platform designed to help Americans find lower-cost alternatives for brand-name prescription drugs, David Merritt, senior vice president of External Affairs at the Blue Cross Blue Shield Association, issued the statement below:
“President Trump’s leadership to launch TrumpRx underscores the urgency of lowering drug prices for American families who are struggling with the rising cost of health care. This will be a huge benefit for millions of Americans who do not have access to insurance coverage. For those who are covered, they also need urgent help to afford their medications, and TrumpRx can help drive down prescription drug costs for everyone.
“The Blue Cross Blue Shield Association has outlined a clear roadmap to make care more affordable. Increasing competition, speeding generics to the market, and expanding biosimilars to patients can deliver lower prices. We are eager to continue working with the Administration and leaders in Congress to deliver meaningful cost relief for patients.”
About Blue Cross Blue Shield Association
The Blue Cross Blue Shield Association is a national federation of independent, community-based and locally operated Blue Cross and Blue Shield companies that collectively provide health care coverage for one in three Americans.